Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03364621 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Study acronym: COMPARISON
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jun 29, 2026 → Jun 29, 2027
See other at-risk trials from University Health Network, Toronto

Record History

  1. Primary and study completion pushed from Jun 29, 2026 to Jun 29, 2027 Eligibility criteria expanded, about 12 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 12 words
  2. Primary and study completion dates: Jun 29, 2025 to Jun 29, 2026v9
  3. Primary and study completion dates: Jun 29, 2024 to Jun 29, 2025v8
  4. Primary and study completion dates: Aug 29, 2023 to Jun 29, 2024v7
  5. Primary and study completion dates: Aug 29, 2022 to Aug 29, 2023v6
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 20 to confirmed 17 · Site details revised at 2 of 2 sitesv4 Show 2 more changesShow less
    • Enrollment target: estimated 20 to confirmed 17
    • Site details revised at 2 of 2 sites
  3. Site details revised at 1 of 2 sitesv3
  4. Site contacts updated at 1 of 2 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective study investigating the disease course of patients with colorectal cancer that have had their cancer spread to their liver. The aim of this study is find potential biomarkers for disease recurrence and therapeutic targets for prognostic information.
Trial Details
NCT Number NCT03364621
Lead Sponsor University Health Network, Toronto
Collaborators: Terry Fox Research Institute, British Columbia Cancer Agency
Conditions Colorectal Cancer, Colorectal Cancer Metastatic, Hepatic Metastases
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov